A proper diagnosis of MODY (1-2% of all diabetes cases) confirmed by genetic testing is crucial to introduce tailored treatment. Patient selection for testing should be performed precisely. The aim of the thesis was to search for new tools that could be applied in differential diabetes diagnosis management, including one based on genetically determined different therapeutic response. In the study ghrelin level as a biomarker of diabetes types, the utility of MODY Probability Calculator in probands of families with early-onset autosomal dominant diabetes and the response to a single dose of dapagliflozin were assessed. It was found that ghrelin level is associated with types of diabetes, the use of MODY Probability Calculator in a group of probands from families with early-onset autosomal dominant diabetes would not substantially improve the patients selection process for genetic testing and that dapagliflozin seems to be effective in GCK-MODY.
Jul 6, 2022
Mar 19, 2021
|ZB-132212||Jul 6, 2022|
Porter,Robert S. (ed -in-chief) Kaplan,Justin L.(senior assistant ed ).